Ingevity (NYSE:NGVT) Issues Quarterly Earnings Results, Misses Estimates By $0.16 EPS

Ingevity (NYSE:NGVT) posted its earnings results on Wednesday. The company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.74 by ($0.16), Zacks reports. Ingevity had a positive return on equity of 103.69% and a negative net margin of 5.14%.The company had revenue of $255.10 million for the quarter, compared to the consensus estimate of $257.27 million. Ingevity updated its FY 2026 guidance to 4.800-5.20 EPS.

Ingevity Price Performance

NYSE:NGVT traded down $1.25 during trading hours on Wednesday, reaching $69.87. 395,177 shares of the company were exchanged, compared to its average volume of 302,218. The company has a market capitalization of $2.51 billion, a P/E ratio of -38.39 and a beta of 1.34. The company has a debt-to-equity ratio of 8.39, a current ratio of 1.27 and a quick ratio of 0.80. The business has a 50 day moving average of $66.52 and a 200 day moving average of $58.83. Ingevity has a 1-year low of $28.49 and a 1-year high of $77.46.

Analysts Set New Price Targets

NGVT has been the topic of several research analyst reports. Zacks Research raised shares of Ingevity to a “hold” rating in a research note on Tuesday, December 16th. Wall Street Zen lowered Ingevity from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Wells Fargo & Company lifted their price objective on shares of Ingevity from $60.00 to $65.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ingevity in a report on Thursday, January 22nd. Finally, BMO Capital Markets increased their target price on Ingevity from $64.00 to $70.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 10th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $67.50.

Institutional Investors Weigh In On Ingevity

Several institutional investors and hedge funds have recently bought and sold shares of NGVT. Global Retirement Partners LLC acquired a new stake in Ingevity during the 4th quarter worth about $27,000. Meeder Asset Management Inc. bought a new stake in Ingevity in the fourth quarter valued at $33,000. Geneos Wealth Management Inc. boosted its position in shares of Ingevity by 85.8% during the 2nd quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock worth $36,000 after purchasing an additional 387 shares in the last quarter. Headlands Technologies LLC acquired a new stake in shares of Ingevity in the 2nd quarter valued at about $46,000. Finally, Kestra Advisory Services LLC acquired a new position in Ingevity during the 4th quarter worth approximately $47,000. Institutional investors own 91.59% of the company’s stock.

Ingevity Company Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.